TEAR - TearLab Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
0.106
+0.001 (+0.95%)
At close: 3:38PM EDT
Stock chart is not supported by your current browser
Previous Close0.105
Open0.105
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.105 - 0.106
52 Week Range0.100 - 1.490
Volume57,440
Avg. Volume56,875
Market Cap1.144M
Beta (3Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-1.159
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    TearLab Update on 510(k) for U.S. FDA Clearance of Discovery™ MMP-9 Test

    TearLab Corporation (TEAR) (“TearLab” or the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has determined that the TearLab Discovery™ MMP-9 test, has not met the criteria for substantial equivalence based upon data and information submitted by TearLab in its 510(k) submission. “We understand the FDA’s position and are encouraged by the clear guidance they have provided. The TearLab Discovery platform is designed to enable eye care professionals to assess multiple biomarkers in human tears with nanoliter volume tear collection.

  • Associated Press2 months ago

    TearLab: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 6 cents. The ophthalmic device company posted revenue of $6.4 million in the period. In the final minutes of trading on Thursday, ...

  • GlobeNewswire2 months ago

    TearLab Corporation Reports Second Quarter and First Half 2018 Financial Results

    SAN DIEGO, Aug. 09, 2018-- TearLab Corporation today reported its consolidated financial results for the second quarter ended June 30, 2018. All dollar amounts are expressed in U.S. currency and results ...

  • Associated Press5 months ago

    TearLab: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 9 cents. The ophthalmic device company posted revenue of $6.4 million in the period. The company's shares closed at 24 cents. A year ...

  • Associated Press7 months ago

    TearLab reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 63 cents. Losses, adjusted for asset impairment costs, came to 55 cents per share. The ophthalmic device company posted revenue of ...

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Aphria, Centric Health, Helix BioPharma and TearLab

    NEW YORK, NY / ACCESSWIRE / February 23, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • TearLab Corp. :TEAR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube11 months ago

    TearLab Corp. :TEAR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis TearLab Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of TearLab Corp. – STAAR Surgical Company, Atrion Corporation and Vuzix Corporation (STAA-US, ATRI-US and VUZI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 6.52 ... Read more (Read more...)

  • Thomson Reuters StreetEvents11 months ago

    Edited Transcript of TEAR earnings conference call or presentation 13-Nov-17 9:30pm GMT

    Q3 2017 TearLab Corp Earnings Call

  • Associated Press11 months ago

    TearLab reports 3Q loss

    The San Diego-based company said it had a loss of 67 cents per share. The ophthalmic device company posted revenue of $6.5 million in the period. In the final minutes of trading on Monday, the company's ...

  • Who Are TearLab Corporation’s (TEAR) Major Shareholders?
    Simply Wall St.last year

    Who Are TearLab Corporation’s (TEAR) Major Shareholders?

    In this analysis, my focus will be on developing a perspective on TearLab Corporation’s (NASDAQ:TEAR) latest ownership structure, a less discussed, but important factor. The impact of a company’s ownershipRead More...